In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for ...

GLP-1RAs were associated with improved quality of life and emotional eating behaviors among individuals with overweight and obesity.

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is ...

aCancer and Medicine, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark bStatistics and Data Analysis, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark ...

aDepartments of Surgery, New York University, New York, NY, USA bDepartment of Medicine, New York University, New York, NY, USA ...

Logistic regression models were utilized to control for potential confounders such as sex, reporter type, number of suspect drugs, and suspected GLP-1 RA agents. Data analysis categorized 5 ...

In the face of skyrocketing costs, Virta sets new standard for employers and health plans aiming to address obesity and GLP-1 spending, with no financial risk Virta Health, a clinical leader in ...

This partnership aims to address the growing demand for alternatives to GLP-1 drugs, as many patients face rapid weight regain after stopping these treatments. Revita, an outpatient endoscopic ...

Data were included for 85,015 adults with a body mass index ≥30 kg/m 2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023. Patients prescribed ...